SignPath Pharma, Inc.
Proprietary platform for designing and manufacturing glycosylated therapeutic proteins with optimized pharmacokinetics and immunogenicity
- Sector
- Biotech
- Headquarters
- Sandy, UT
- Founded
- 2006
- Latest Form D
- $1.6M, May 2021
- Total capital
- $4.5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $4.5M
- 9 Form D · last May 2021
- 66 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 20
- 20 pending · first 2015
- Rank in peer group#13 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 9th filing$1.6M
- Private capital raisedForm D · SEC · 8th filing$525K
- Private capital raisedForm D · SEC · 7th filing$235K
- Private capital raisedForm D · SEC · 6th filing$245K
- Private capital raisedForm D · SEC · 5th filing$320K
- Private capital raisedForm D · SEC · 4th filing$1M
- Private capital raisedForm D · SEC · 3rd filing$580K
- Private capital raisedForm D · SEC · 2nd filing$25K
- Offering registeredForm D · SEC · 1st filing$1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#13 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Peter P. SordilloResearcherExecutive OfficerLinked by 2 patents
- Lawrence D. HelsonResearcherExecutive Officer, DirectorLinked by 1 patent
- Arthur Ballon, Ph.DExecutive Officer, DirectorNamed in SEC Form D filings
- Arthur P. BollonDirectorNamed in SEC Form D filings
- Arthur P. Bollon, Ph.DDirectorNamed in SEC Form D filings
- Beth P. HechtDirectorNamed in SEC Form D filings
Show all 18 people
- Jack D. LevineDirectorNamed in SEC Form D filings
- Jack P. Levine, CPADirectorNamed in SEC Form D filings
- Kai LarsonExecutive Officer, DirectorNamed in SEC Form D filings
- Kai P. Larson, JDExecutive OfficerNamed in SEC Form D filings
- Meyers P. Associates L.P.PromoterNamed in SEC Form D filings
- Meyers Associates, L.P.PromoterNamed in SEC Form D filings
- N/A P. Meyers Associates, L.P.PromoterNamed in SEC Form D filings
- None P. Meyers Associates, L.P.PromoterNamed in SEC Form D filings
- Robert P. SagusoDirectorNamed in SEC Form D filings
- Robert SegusoExecutive Officer, DirectorNamed in SEC Form D filings
- Timothy P. ToloukianExecutive OfficerNamed in SEC Form D filings
- Timothy TouloukianExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 20 granted of 40- PendingDosing Regimens for Treatment of GlioblastomaUSPTOApplication 19450053
- GrantedCardioprotective Lipid and Method of UseUSPTOUS 12,617,809
- GrantedDosing Regimens for Treatment of Proliferative DisordersUSPTOUS 12,551,436
Show all 40 patent records
- Dosing Regimens for Treatment of GlioblastomaMay 28, 2026 · Application 19450053Pending
- Cardioprotective Lipid and Method of UseMay 5, 2026 · US 12,617,809Granted
- Dosing Regimens for Treatment of Proliferative DisordersFeb 17, 2026 · US 12,551,436Granted
- Liposomal Mitigation Of Drug-induced Inhibition Of The Cardiac Ikr ChannelJun 11, 2024 · US 12,004,868Granted
- Treatment For Malignant Pleural Effusion In HumansJun 6, 2024 · Application 18263649Pending
- Lipids That Reduce Lung Damage, Improve Pulmonary Function And Decrease Pro-inflammatory CytokinesMar 21, 2024 · Application 18260012Pending
- Cardioprotective Lipids And Methods Of UseJan 25, 2024 · Application 18457037Pending
- Dosing Regimens for Treatment of Proliferative DisordersNov 14, 2023 · US 11,813,356Granted
- Prevention Of Drug-induced Atrio-ventricular BlockNov 7, 2023 · US 11,806,401Granted
- Cardiopathy-reducing Phosphodiester LipidsSep 5, 2023 · US 11,746,119Granted
- Cardiopathy-reducing Phosphodiester LipidsMay 9, 2023 · US 11,643,424Granted
- Cardiopathy-reducing Phosphodiester LipidsApr 13, 2021 · US 10,975,111Granted
- Suppression of Cytokine Release and Cytokine StormNov 19, 2020 · Application 16945195Pending
- Liposomal Mitigation Of Drug-induced Long Qt Syndrome And Potassium Delayed-rectifier CurrentApr 14, 2020 · US 10,617,639Granted
- Liposomal Mitigation of Drug-Induced Inhibition of the Cardiac IKR ChannelApr 9, 2020 · Application 16700558Pending
- Treatment For GlioblastomaFeb 13, 2020 · Application 16660263Pending
- Liposomal Mitigation Of Drug-induced Inhibition Of The Cardiac Ikr ChannelJan 14, 2020 · US 10,532,045Granted
- Protective Effect Of Dmpc, Dmpg, Dmpc/dmpg, Lysopg And Lysopc Against Drugs That Cause ChannelopathiesDec 26, 2019 · Application 16561195Pending
- Treatment For GlioblastomaNov 26, 2019 · US 10,485,768Granted
- Liposomal Mitigation of Drug-Induced Long QT Syndrome and Potassium Delayed-Rectifier CurrentOct 24, 2019 · Application 16433555Pending
- Protective Effect Of Dmpc, Dmpg, Dmpc/dmpg, Lysopg And Lysopc Against Drugs That Cause ChannelopathiesOct 22, 2019 · US 10,449,193Granted
- Liposomal Mitigation Of Drug-induced Long Qt Syndrome And Potassium Delayed-rectifier CurrentJul 23, 2019 · US 10,357,458Granted
- Liposomal Mitigation Of Drug-induced Inhibition Of The Cardiac Ikr ChannelJul 16, 2019 · US 10,349,884Granted
- Protective Effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC Against Drugs that Cause ChannelopathiesJun 6, 2019 · Application 16246232Pending
- Protective Effect Of Dmpc, Dmpg, Dmpc/dmpg, Lysopg And Lysopc Against Drugs That Cause ChannelopathiesMar 26, 2019 · US 10,238,602Granted
- Compositions And Method For Reducing CardiotoxicityJan 10, 2019 · Application 16028112Pending
- Liposomal Curcumin for Treatment of DiseasesNov 8, 2018 · Application 16007283Pending
- Protective Effect Of Dmpc, Dmpg, Dmpc/dmpg, Lysopg And Lysopc Against Drugs That Cause ChannelopathiesNov 6, 2018 · US 10,117,881Granted
- Liposomal Curcumin For Treatment Of DiseasesJun 26, 2018 · US 10,004,687Granted
- Sphingosine Kinase Inhibitors And Ceramide For Maintenance Therapy Of GlioblastomaSep 7, 2017 · Application 15439405Pending
- Liposomal Mitigation Of Drug-induced Long Qt Syndrome And Potassium Delayed-rectifier CurrentJun 20, 2017 · US 9,682,041Granted
- Curcumin For Treating Intervertebral Disc DiseaseOct 6, 2016 · Application 15082708Pending
- Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite TetrahydrocurcuminDec 31, 2015 · Application 14851966Pending
- Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite TetrahydrocurcuminOct 27, 2015 · US 9,170,257Granted
- Curcumin-er, A Liposomal-plga Sustained Release Nanocurcumin For Minimizing Qt Prolongation For Cancer TherapySep 22, 2015 · US 9,138,411Granted
- Curcumin-er, A Liposomal-plga Sustained Release Nanocurcumin For Minimizing Qt Prolongation For Cancer TherapySep 17, 2015 · Application 14725624Pending
- Intravenous Synthetic Curcumin (s-curcumin) For The Treatment Of Proliferative DisordersMay 28, 2015 · Application 14550672Pending
- Intravenous Infusion of Curcumin and a Calcium Channel BlockerAug 21, 2014 · Application 14265669Pending
- Intravenous Curcumin And Derivatives For Treatment Of Neurodegenerative And Stress DisordersApplication PCTUS2011029393Pending
- Cardioprotective Lipids And Methods Of UseApplication PCTUS2024041253Pending
Related companies, and why
- NEUROENE THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- ACTORIUS PHARMACEUTICALS, LLCSimilar federal contract value in Biotech · null in contracts
- Black Bear Energy, Inc.Similar federal contract value in Biotech · null in contracts
- OverT Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Gila Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- SANARENTERO LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .